|
Donna--It was an article posted by Lani--you can find full article by searching threads under her name.
The three drugs were: Gefitinib (marketed as Iressa),
herceptin, and another drug called pertuzumab.
Conclusion: Combined treatment with gefitinib, trastuzumab, and pertuzumab to block signals from all HER homo- and heterodimers inhibited growth of HER2-overexpressing xenografts statistically significantly better than single agents and dual combinations.
A clinical study using drug combinations in newly diagnosed patients with HER-2 positive breast cancer will start soon under the direction of physicians at BCM's Breast Center, said Osborne.
This is a real long shot, but it might help knowing about this.
|
Threaded Mode